Exposure to increased neighborhood violence has the power to change the glucocorticoid receptor (GR) for the stress hormone, cortisol, which may influence the aggressiveness of lung cancer, according to data presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Men who illicitly used steroids to boost muscle size and physical performance and have stopped in the past year have impaired sexual function compared with men currently using steroids, according to a study being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
A novel male contraceptive gel combining two hormones, segesterone acetate (named Nestorone) and testosterone, suppresses sperm production faster than similar experimental hormone-based methods for male birth control, according to a new study.
Testosterone appears protective against developing type 2 diabetes in men who are overweight or obese and under age 65, but not in men over that age, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Researchers from Fred Hutch Cancer Center have found that active surveillance for prostate cancer patients with a low risk of progression is an effective alternative to immediate surgery or radiation to manage the disease.
The choices that Bruce Gold faced last December to resolve debilitating symptoms from a severely enlarged prostate were to keep using a catheter or have an invasive surgery with unreliable results and a high risk of complications and lingering side effects.
No means no when it comes to sex. But what happens when a woman makes a more passive response to a sexual advance? According to new research from Binghamton University, State University of New York, men differ in how they interpret these types of responses, and men who display hostile masculinity, known commonly as “toxic masculinity,” tend to act on them regardless of whether or not they think it’s consensual.
At a time when health resources are at a premium and need to be wisely allocated, health professionals must find points within men’s lives when it makes the most sense to intervene and advocate for preventive care for promoting better health outcomes.
Researchers at the University of Michigan Rogel Cancer Center have developed a new urine-based test that addresses a major problem in prostate cancer: how to separate the slow-growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.
Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored the first large-scale study that revealed racial disparities in treatment, survival, and access to care among patients with metastatic castration-sensitive prostate cancer (mCSPC) since the first novel hormonal therapy was approved in 2018.
NIBIB-supported researchers have developed a smart nanoprobe designed to infiltrate prostate tumors and send back a signal using an optical imaging technique known as Raman spectroscopy.
A study by Joemy Ramsay, PhD, suggests families with infertile male relatives may face elevated cancer risks. Tapping into genetic data, families could help personalize cancer risk assessments.
Microvascular function is lower in Black men following a recent diagnosis of prostate cancer, compared to white men.
Annual prostate cancer cases worldwide are projected to double by the year 2040, and annual deaths are projected to increase by 85% – mainly among men in low- and middle-income countries. A commissioned report in The Lancet seeks to guide cancer experts worldwide on how to manage this massive influx of prostate cancer patients.
Benyi Li, MD, PhD, professor in the Department of Urology and member of The University of Kansas Cancer Center, has received a nearly $1.4 million grant from the U.S. Department of Defense to develop a short peptide-based therapy for prostate cancer patients.
Vignesh T. Packiam, MD, director of Clinical and Translational Research in Urologic Oncology and a urologic oncologist in the Urologic Oncology Program at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, the state’s leading cancer program and only NCI-designated Comprehensive Cancer Center, shares about testicular cancer and what men should know.
Desai Sethi Urology Institute (DSUI) Scientific Director Nima Sharifi, M.D., authored an invited commentary in JAMA Network Open related to a new Million Veteran Program study on the HSD3B1 genotype, an allele he helped discover more than 10 years ago.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
20221027104337.jpg&width=400&height=400)